Technical Analysis for XBIO - Xenetic Biosciences, Inc.

Grade Last Price % Change Price Change
C 3.95 -1.00% -0.04
XBIO closed up 2.31 percent on Wednesday, November 20, 2024, on 22 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Flat Up Up

Date Alert Name Type % Chg
20 DMA Support Bullish -1.00%
Crossed Above 200 DMA Bullish -1.00%
Crossed Above 50 DMA Bullish -1.00%
200 DMA Resistance Bearish 1.28%
Fell Below 50 DMA Bearish 1.28%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.28%
20 DMA Support Bullish 1.28%
MACD Bullish Signal Line Cross Bullish 1.28%
Calm After Storm Range Contraction 1.28%
Oversold Stochastic Weakness 1.28%

   Recent Intraday Alerts

Alert Time
Gap Down Partially Closed 32 minutes ago
Gap Down Closed 32 minutes ago
Gapped Down (Partial) about 3 hours ago
20 DMA Support about 3 hours ago
10 DMA Support about 3 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Xenetic Biosciences, Inc. Description

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company's platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company's technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company's lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Pharmaceutical Products FDA Acute Myeloid Leukemia Kidney Disease Dialysis Anemia Chronic Kidney Disease Drug Therapies Platform Technologies Endometrial Cancer Refractory Acute Myeloid Leukemia Erythropoietin Growth Factors

Is XBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.175
52 Week Low 2.78
Average Volume 22,662
200-Day Moving Average 3.97
50-Day Moving Average 3.91
20-Day Moving Average 3.87
10-Day Moving Average 3.86
Average True Range 0.35
RSI (14) 53.05
ADX 20.86
+DI 24.64
-DI 13.60
Chandelier Exit (Long, 3 ATRs) 3.55
Chandelier Exit (Short, 3 ATRs) 4.63
Upper Bollinger Bands 4.23
Lower Bollinger Band 3.50
Percent B (%b) 0.67
BandWidth 18.75
MACD Line 0.00
MACD Signal Line -0.02
MACD Histogram 0.0144
Fundamentals Value
Market Cap 6.15 Million
Num Shares 1.54 Million
EPS -2.90
Price-to-Earnings (P/E) Ratio -1.38
Price-to-Sales 2.53
Price-to-Book 0.55
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.41
Resistance 3 (R3) 4.39 4.24 4.34
Resistance 2 (R2) 4.24 4.13 4.25 4.32
Resistance 1 (R1) 4.11 4.06 4.18 4.13 4.29
Pivot Point 3.96 3.96 3.99 3.97 3.96
Support 1 (S1) 3.83 3.85 3.90 3.85 3.69
Support 2 (S2) 3.68 3.78 3.69 3.66
Support 3 (S3) 3.55 3.68 3.64
Support 4 (S4) 3.57